Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metoclopramide intranasal - Evoke Pharma

Next Previous
X
Search
Drug Profile

Metoclopramide intranasal - Evoke Pharma

Alternative Names: Emitasol; EVK 001; Gimoti; GIMOTI®; Pramidin

Latest Information Update: 17 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer EVERSANA Life Science; Evoke Pharma; Questcor Pharmaceuticals
  • Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Diabetic gastroparesis
  • Discontinued Gastroparesis

Most Recent Events

  • 14 Nov 2023 Evoke Pharma has patent protection for metoclopramide nasal spray entitled as "Nasal Formulations of Metoclopramide" in the US
  • 14 Sep 2023 Evoke Pharma receives Notice of Allowance for nasal formulations of metoclopramide in USA
  • 21 Apr 2023 Evoke Pharma has a patent protection for metoclopramide and its characteristics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top